**Author details**

Fouad Aoun\* , Marc Zanaty, Alexandre Peltier and Roland van Velthoven

\*Address all correspondence to: fouad.aoun@bordet.be

Department of Urology, Free University of Brussels (ULB), Brussels, Belgium

## **References**


[6] Turpen R, Rosser CJ. Focal therapy for prostate cancer: revolution or evolution? BMC Urology 2009;9:2.

focal therapy, we demonstrated a biochemical recurrence free survival of 100%, 89%, 82.7% at 1, 2 and 3 years respectively, with an overall and cancer specific survival of 100% [19].

As any other interventional technique, there are some limitations for HIFU that must be mentioned. First, there are factors to take into account such as collateral damage to the tissues and the fact that the technique is operator dependent [37]. Second, the lack of comparative trials precludes any conclusion regarding the added value of HIFU treatment compared to active surveillance or radical therapies. Urological societies recommend using focal HIFU in controlled trials in order to provide the needed answers. In the future, the use of focal HIFU will not be limited to prostate cancer but will widespread to other applications. The two most interested research topics are focused ultrasound mediated targeted drug delivery and the

, Marc Zanaty, Alexandre Peltier and Roland van Velthoven

[1] Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A. Novel approaches to improve prostate cancer diagnosis and manage‐

[2] Kazer MW, Psutka SP, Latini DM, Bailey DE. Psychosocial aspects of active surveil‐

[3] Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for

[4] Boorjian SA, Eastham JA, Graefen M, et al. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol

[5] Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment

localized prostate cancer. N Engl J Med. 2012 Jul 19;367(3):203-13.

for localized prostate cancer. N Engl J Med 2013;368(5):436-445.

Department of Urology, Free University of Brussels (ULB), Brussels, Belgium

**11. Limitations and Future perspectives**

transient and reversal opening of the blood-brain barrier

\*Address all correspondence to: fouad.aoun@bordet.be

ment in early-stage disease. BJUI 2012;109(2):1-7.

lance. Curr Opin Urol. 2013 May;23(3):273-7.

2012;61(4):664-675.

**Author details**

8 Updates on Cancer Treatment

Fouad Aoun\*

**References**


prostate cancer: outcome from the @-Registry. Prostate Cancer Prostatic Dis. 2012 Sep;15(3):256-9.

[33] Pfeiffer D, Berger J, Gross AJ. Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes. BJU Int. 2012 Dec;110(11):1702-7

[20] Hynynen K, McDannold N. MRI-guided focused ultrasound for local tissue ablation and other image-guided interventions. In:Wu J, Nyborg WL, eds. Emerging thera‐

peutic ultrasound, 1st ed. Singapore: World Scientific Publishing, 2006:167-218

2004;6:229-248

2007;93:111-129.

& Sons, 2004:407-456.

Urol Assoc J. 2010 Aug;4(4):232-6.

dx.doi.org/10.1155/2014/186782

cancer. Eur Urol. 2010 Dec;58(6):803-15.

Int J Radiat Oncol Biol Phys. 2006; 65:965–974.

311-22.

10 Updates on Cancer Treatment

1205-13.

[21] Dalecki D. Mechanical bioeffects of ultrasound. Annu Rev Biomed Eng

[22] Jenne, J.W., T. Preusser, and M. Gunther, High-intensity focused ultrasound: princi‐ ples, therapy guidance, simulations and applications. Z Med Phys, 2012. 22(4): p.

[23] Cordeiro, E.R., et al., High-intensity focused ultrasound (HIFU) for definitive treat‐

[24] ter Haar GR. Therapeutic application of ultrasound. Prog Biophys Mol Biol

[25] ter Haar GR. Therapeutic and surgical applications. In: Hill CR, Bamber JC, ter Haar GR, eds. Physical principles of medical ultrasound, 2nd ed. West Sussex: John Wiley

[26] Rebillard, X., et al., High-intensity focused ultrasound in prostate cancer; a systemat‐ ic literature review of the French Association of Urology. BJU Int, 2008. 101(10): p.

[27] Lukka H, Waldron T, Chin J, Mayhew L, Warde P, Winquist E, Rodrigues G, Shaye‐ gan BHigh-intensity focused ultrasound for prostate cancer: a practice guideline. Can

[28] NICE guidelines 2012: Focal therapy using high-intensity focused ultrasound for lo‐

[29] Limani K, Aoun F, Holz S, Paesmans M, Peltier A, van Velthoven R. Single High In‐ tensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clini‐ cally Localized Prostate Cancer: 10-Year Outcomes. Prostate Cancer 2014,http://

[30] Warmuth M, Johansson T, Mad P. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate

[31] Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following ra‐ diotherapy with or without hormonal therapy in men with clinically localized pros‐ tate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

[32] Blana A, Robertson CN, Brown SC, Chaussy C, Crouzet S, Gelet A, Conti GN, Ganz‐ er R, Pasticier G, Thuroff S, Ward JF. Complete high-intensity focused ultrasound in

calised prostate cancer. Issued in guidance.nice.org.uk/ipg424

ment of prostate cancer. BJU Int, 2012. 110(9): p. 1228-42.

